1. Future Microbiol. 2015 Jul;10:1111-23. doi: 10.2217/fmb.15.39. Epub 2015 Jun 29.

Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical
development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics
and clinical efficacy.

Van Bambeke F(1).

Author information: 
(1)Pharmacologie cellulaire et moléculaire, Louvain Drug Research Institute,
Université catholique de Louvain, Avenue E Mounier 73 B1.73.05, 1200 Brussels,

ABSTRACT  Delafloxacin is a fluoroquinolone lacking a basic substituent in
position 7. It shows MICs remarkably low against Gram-positive organisms and
anaerobes and similar to those of ciprofloxacin against Gram-negative bacteria.
It remains active against most fluoroquinolone-resistant strains, except
enterococci. Its potency is further increased in acidic environments (found in
many infection sites). Delafloxacin is active on staphylococci growing
intracellularly or in biofilms. It is currently evaluated as an intravenous and
intravenous/oral stepdown therapy in Phase III trials for the treatment of
complicated skin/skin structure infections. It was also granted as Qualified
Infectious Disease Product for the treatment of acute bacterial skin and skin
structure infections and community-acquired bacterial pneumonia, due to its high 
activity on pneumococci and atypical pathogens.

PMID: 26119479  [PubMed - in process]